Pheon Therapeutics Secures $120M Funding to Revolutionize Cancer Treatment with Next-Gen ADC Technology

Pheon Therapeutics is thrilled to announce that it has successfully raised $120 million in its latest funding round, a significant milestone that will empower the company to further its innovative research in antibody-drug conjugates (ADCs). Leveraging over two decades of ADC expertise, Pheon is dedicated to developing next-generation therapies aimed at effectively treating solid tumors and liquid cancers that remain resistant to conventional treatments. Unlike the traditional “one size fits all” approach, Pheon adopts a meticulous methodology in ADC engineering, integrating both novel and clinically validated monoclonal antibodies (mAbs) with advanced linkers and payloads derived from their proprietary platform. This strategic blend is designed to maximize both safety and efficacy for various therapeutic targets. The funding will specifically accelerate the progress of Pheon’s lead program, which focuses on a novel target that is widely overexpressed in numerous solid tumors, with the goal of advancing the lead agent to Investigational New Drug (IND) status within the next 18 months. Additionally, Pheon Therapeutics is backed by a formidable group of specialist healthcare investors, including Atlas Venture, Brandon Capital, Forbion, and Research Corporation Technologies. This capital infusion not only enhances the company’s robust pipeline but also solidifies its position in the highly competitive ADC landscape. With state-of-the-art medicinal chemistry laboratories in London and a commercial office in Boston, Pheon is poised to make significant strides in oncology, offering hope to patients whose conditions have historically lacked viable treatment options.